Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-017860
Filing Date
2025-06-20
Accepted
2025-06-20 16:27:00
Documents
1
Period of Report
2025-06-20

Document Format Files

Seq Description Document Type Size
1 form4-06202025_080655.html 4  
1 form4-06202025_080655.xml 4 3906
  Complete submission text file 0001415889-25-017860.txt   5600
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Issuer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258
Business Address
ZELDIS JEROME B (Reporting) CIK: 0001433982 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-14778 | Film No.: 251061772